Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Ewing sarcoma/PNET
Stage/Subtype:  recurrent Ewing sarcoma/PNET
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872
Aerosol IL-2 for Pulmonary Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PST-001, NCT01962103
BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-00804, ADVL1411, UM1CA097452, NCT02116777
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 moths to 29 years
Sponsor: NCI, Other
Protocol IDs: 2013-171, NCI-2014-01149, P30CA022453, NCT02173093
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-01222, ADVL1412, UM1CA097452, NCT02304458
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-02605, CDR0000686608, COG-ACNS0821, ACNS0821, U10CA180886, U10CA098543, NCT01217437
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: 11-183, NCT01492673
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116731, NCT01956669
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SARC024, NCT02048371
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: STIR Trial, NCT02100891
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: SARC028, NCT02301039
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Phase: Phase II
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ONC2014-001, 1R44CA183075-01A1, NCT02423863
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: RADIANT, NCI-2012-00588, NCT01625351
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01165, CDR0000737378, 12-083, 9172, P30CA008748, U01CA069856, NCT01643278
Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 100
Sponsor: Other
Protocol IDs: 20110462, NCT01803152
Start Over